Last reviewed · How we verify
ADX-038
ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Treatment of autoimmune diseases.
At a glance
| Generic name | ADX-038 |
|---|---|
| Also known as | siRNA |
| Sponsor | ADARx Pharmaceuticals, Inc. |
| Drug class | PI3K delta and gamma inhibitor |
| Target | PI3K delta and gamma |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, ADX-038 aims to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases. This mechanism is thought to be beneficial in conditions where PI3K signaling plays a key role.
Approved indications
- Treatment of autoimmune diseases
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Phase 2 Study of ADX-038 in Participants With Geographic Atrophy (PHASE2)
- Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease (PHASE2)
- Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADX-038 CI brief — competitive landscape report
- ADX-038 updates RSS · CI watch RSS
- ADARx Pharmaceuticals, Inc. portfolio CI